Alkermes | Investor Day Presentation Deck

Slide schematic 6/6

callout 1/1 chart 3/3 disclaimer 1/1 title 1/1

Components 6

primary bar-vertical bar-vertical bar-vertical disclaimer headline

Tools 1

chart/bar-vertical: CD8+ T Cells Nemvaleukin Fold Change from Baseline, chart/bar-vertical: NK Cells Nemvaleukin Fold Change from Baseline, chart/bar-vertical: Tregs Nemvaleukin Fold Change from Baseline

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 0

∅

No frameworks

No framework match is anchored to this slide.

Find anything

The slide highlights the efficacy of the SC 3 mg q7d regimen in expanding effector cells compared to IV administration.